Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]

1793 reported adverse events

Drugs of this class: CLESROVIMAB NIRSEVIMAB

These side effects are most commonly reported by patients taking drugs of the Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 324
1 RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS 302
2 RESPIRATORY SYNCYTIAL VIRUS INFECTION 253
3 INCORRECT DOSE ADMINISTERED 234
4 BRONCHIOLITIS 157
5 PYREXIA 116
6 COUGH 112
7 EXTRA DOSE ADMINISTERED 84
8 EXPIRED PRODUCT ADMINISTERED 50
9 RESPIRATORY SYNCYTIAL VIRUS TEST POSITIVE 50
See all common reactions for Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]

Drugs of the Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ANTIBODY-DEPENDENT ENHANCEMENT 1 1.0000
1 BACTERIAL DACRYOCYSTITIS 1 0.5000
2 RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS 302 0.3862
3 CONGENITAL FIBROSARCOMA 1 0.3333
4 KAPOSIFORM HAEMANGIOENDOTHELIOMA 1 0.3333
5 METAPNEUMOVIRUS BRONCHIOLITIS 3 0.2727
6 RESPIRATORY SYNCYTIAL VIRUS IMMUNISATION 2 0.2000
7 ANTIVIRAL PROPHYLAXIS 2 0.1818
8 IMMATURE PLATELET FRACTION INCREASED 2 0.1667
9 RESPIRATORY SYNCYTIAL VIRUS BRONCHITIS 18 0.1324
See all enriched reactions for Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]